In most patients with Ph+ CML the disease can be kept under control with imatinib or with second‐ or third generation BCR::ABL1 TKI.4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.